A comparison of model-free phase I dose escalation designs for dual-agent combination therapies

URN to cite this document:: urn:nbn:de:bvb:355-epub-777767
DOI to cite this document:: 10.5283/epub.77776

Barnett, Helen ; George, Matthew ; Skanji, Donia ; Saint-Hilary, Gaelle ; Jaki, Thomas

; Mozgunov, Pavel

License: Creative Commons Attribution 4.0
PDF - Published Version
(1MB)

Date of publication of this fulltext: 22 Sep 2025 06:41

Alternative links to fulltext:DOI Publisher

Details

Preview

Export bibliographical data

Abstract

It is increasingly common for therapies in oncology to be given in combination. In some cases, patients can benefit from the interaction between two drugs, although often at the risk of higher toxicity. A large number of designs to conduct phase I trials in this setting are available, where the objective is to select the maximum tolerated dose combination. Recently, a number of model-free (also ...